Abstract：
UNASSIGNED: To determine if treatment of co-occurring adult ADHD and Cannabis Use Disorder (CUD) with extended-release mixed amphetamine salts (MAS-ER) would be effective at improving ADHD symptoms and promoting abstinence.
UNASSIGNED: A 12-week randomized, double-blind, two-arm pilot feasibility trial of adults with comorbid ADHD and CUD (n = 28) comparing MAS-ER (80 mg) to placebo. Main outcomes: ADHD: ≥30% symptom reduction, measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS). CUD: Abstinence during last 2 observed weeks of maintenance phase.
UNASSIGNED: Overall, medication was well-tolerated. There was no significant difference in ADHD symptom reduction (MAS-ER: 83.3%; placebo: 71.4%; p = .65) or cannabis abstinence (MAS-ER: 15.4%; placebo: 0%; p = .27). MAS-ER group showed a significant decrease in weekly cannabis use days over time compared to placebo (p < .0001).
UNASSIGNED: MAS-ER was generally well-tolerated. The small sample size precluded a determination of MAS-ER\'s superiority reducing ADHD symptoms or promoting abstinence. Notably, MAS-ER significantly reduced weekly days of use over time.
UNASSIGNED: A 12-week randomized, double-blind, two-arm pilot feasibility trial of adults with comorbid ADHD and CUD (n = 28) comparing MAS-ER (80 mg) to placebo. Main outcomes: ADHD: ≥30% symptom reduction, measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS). CUD: Abstinence during last 2 observed weeks of maintenance phase.
UNASSIGNED: Overall, medication was well-tolerated. There was no significant difference in ADHD symptom reduction (MAS-ER: 83.3%; placebo: 71.4%; p = .65) or cannabis abstinence (MAS-ER: 15.4%; placebo: 0%; p = .27). MAS-ER group showed a significant decrease in weekly cannabis use days over time compared to placebo (p < .0001).
UNASSIGNED: MAS-ER was generally well-tolerated. The small sample size precluded a determination of MAS-ER\'s superiority reducing ADHD symptoms or promoting abstinence. Notably, MAS-ER significantly reduced weekly days of use over time.
摘要：
■确定使用缓释混合苯丙胺盐（MAS-ER）治疗同时发生的成人ADHD和大麻使用障碍（CUD）是否可以有效改善ADHD症状并促进禁欲。
■一项为期12周的随机研究，双盲,针对患有ADHD和CUD的成人(n=28)进行的双臂试点可行性试验,比较MAS-ER(80mg)和安慰剂。主要结果：ADHD：症状减轻≥30％，通过成人ADHD研究者症状评定量表（AISRS）进行测量。CUD：在维持阶段的最后2周观察期间禁欲。
■总的来说，药物耐受性良好。ADHD症状减轻（MAS-ER：83.3％；安慰剂：71.4％；p=0.65）或大麻禁欲（MAS-ER：15.4％；安慰剂：0％；p=0.27）没有显着差异。与安慰剂相比，MAS-ER组显示每周大麻使用天数随时间显着减少（p<0.0001）。
■MAS-ER一般耐受性良好。样本量小，无法确定MAS-ER的优越性，从而减轻ADHD症状或促进禁欲。值得注意的是,随着时间的推移，MAS-ER显著减少了每周的使用天数。
■一项为期12周的随机研究，双盲,针对患有ADHD和CUD的成人(n=28)进行的双臂试点可行性试验,比较MAS-ER(80mg)和安慰剂。主要结果：ADHD：症状减轻≥30％，通过成人ADHD研究者症状评定量表（AISRS）进行测量。CUD：在维持阶段的最后2周观察期间禁欲。
■总的来说，药物耐受性良好。ADHD症状减轻（MAS-ER：83.3％；安慰剂：71.4％；p=0.65）或大麻禁欲（MAS-ER：15.4％；安慰剂：0％；p=0.27）没有显着差异。与安慰剂相比，MAS-ER组显示每周大麻使用天数随时间显着减少（p<0.0001）。
■MAS-ER一般耐受性良好。样本量小，无法确定MAS-ER的优越性，从而减轻ADHD症状或促进禁欲。值得注意的是,随着时间的推移，MAS-ER显著减少了每周的使用天数。
